Hikma launches XCOPRI cenobamate tablets in the UAE
The first anti-seizure medication with Cenobamate in the UAE treats partial-onset seizures in adults.
See the latest news and media coverage for Hikma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global pharmaceutical company
hikma.comLast updated
In short: Hikma Pharmaceuticals reported growth in 2025 results, secured a major US Supreme Court win on patent labels, and expanded in Ohio.
The first anti-seizure medication with Cenobamate in the UAE treats partial-onset seizures in adults.
The report covers 222 million patients treated, 84 new products, and 18% emissions reduction.
The court effectively ended Amarin's patent infringement lawsuit against Hikma, allowing continued sale of generic icosapent ethyl.
The expansion will create 350 new jobs and is part of $1B in US investments.
Boston Partners FKA Robeco Investment Management, Inc. has reduced its total holding in Hikma Pharmaceuticals PLC to 5.67% from 7.052%, with voting rights attached to...
Explore why Healthcare Stocks are active as UK macro releases and public-finance sensitivity are shaping London trading, with focus on Hikma Pharmaceuticals (LSE:HIK) and Haleon...
Detailed price information for Hikma Pharmaceuticals Plc (HKMPF) from The Globe and Mail including charting and trades.
London, 26 February 2026 - As separately announced today in its full-year results for the financial year ended 31 December 2025, Hikma Pharmaceuticals PLC (LSE...
Track Hikma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Hikma and other trending companies.